The Ron Lanton Report: What Are We Doing This All For?

This episode of The Ron Lanton Report closes out season one by asking the question sitting underneath every prior conversation about trade, innovation, and drug pricing: why are we doing any of this in the first place?

Framing the discussion around what she calls the "prize, not price" of innovation, Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, argues that biopharmaceutical policy only makes sense when it is traced back to its purpose, giving people, not an abstract patient population, solutions to problems that would otherwise define or end their lives. Ron Lanton frames this as the natural capstone to a season spent examining innovation, trade, and pricing issue by issue, without ever stepping back to ask what all of it is for.

The episode reframes affordability not as a single problem to be solved but as a question of timing. Whittington points to the biotech social contract, a concept she credits to Dr. Peter Kolchinsky, in which market-based pricing during a patent-protected exclusivity period is meant to be followed by timely generic or biosimilar entry that drops prices toward the marginal cost of production. Both she and Lanton note that prescription drug prices just recorded their steepest annual decline since 1963, evidence in Whittington's view, that this two-phase system works when it is allowed to play out, even as newer interventions like most-favored-nation pricing and direct-to-consumer pricing remain harder to credit directly, given the absence of anything like a controlled comparison.

The analysis then extends into Whittington's own field of Pharmacoeconomics, where she argues the standard tools for valuing innovation have a significant blind spot: time. Cost-effectiveness models typically anchor on a patient starting treatment at launch and assume that launch price holds constant over that patient's lifetime. In reality, prices move throughout a product's life cycle, like Sovaldi which launched near $80,000 and has already fallen to roughly $10,000 to $15,000 through brand-to-brand competition alone, before any generic has entered. That gap between modeling a patient's lifetime at launch price and modeling a product's full lifecycle, she argues, creates a deeper disconnect between what a model calls an "efficient" price and what actually constitutes an optimal reward for innovation.

Finally, the episode turns to where this constraint goes next. Whittington points to the biosimilar market and cell and gene therapy as the coming test case: small-molecule generics have proven they can deliver steep, fast price declines, but biosimilars have not yet shown the same, even as biologics make up a growing share of the pipeline. She also flags the mismatch between policymakers' and insurers' short, budget-cycle decision windows and the long product lifecycles that innovation actually plays out over, arguing that the only way through is to lean harder on evidence-based, historical-pattern assumptions rather than launch-year snapshots.